A wave of new clinical trial results with broad implications swept over the IFEMA convention center in Madrid, Spain.
About 24,000 participants, from 130 countries, attended the annual congress of the European Society of Medical Oncology (ESMO) — the largest global oncology-focused meetings of the year. In all, there were 1,700 presentations delivered in multiple auditoriums and meeting rooms across the massive convention center.
Among the most important results, known as late-breaking abstracts (LBAs), were findings that could completely change the way patients with lung cancer, melanoma and kidney cancer are treated, along with a host of other findings. There were 55 LBAs.
Now, in the wake of the meeting, physicians and researchers continue to debate how these new findings could impact the care of patients. The clinical trials with the greatest impact were labeled PACIFIC, FLAURA, COMBI-AD, CheckMate 238 and 214, MONARCH3, ARIEL3 and RANGE.
Here’s a round up of CURE
’s coverage of the event:
Increased Abdominal Fat Associated With Higher Cancer Risk
Breast Cancer Risk Nearly Cut in Half For Women With High Cholesterol
Keytruda Bests Chemotherapy in Overall Survival Rates for Bladder Cancer
BRCA Gene Mutation May Harm Fertility Preservation in Women With Breast Cancer
New Treatments Needed for Those Disabled by Advanced Gastric Cancer
New Tool May Help Patients With Cancer Get Earlier Palliative Care
Careers of Young Survivors Can be Disrupted by Late-Emerging Side Effects of Cancer Treatment
Nausea, Vomiting No Longer a Top Chemotherapy Concern Among Patients